logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10561618 B1

PDFFull Text
Date of Patent:
Feb. 18, 2020

Filed:

Apr. 18, 2013

Orally available pharmaceutical formulation suitable for improved management of movement disorders

Applicant:

Contera Pharma Aps, Copenhagen K, DK;

Inventors:

John Bondo Hansen, Jyderup, DK;

Mikael S. Thomsen, Hvidovre, DK;

Jens D. Mikkelsen, Lyngby, DK;

Peter Gudmund Nielsen, Værløse, DK;

Mads Kreilgaard, Farum, DK;

Assignee:

Contera Pharma ApS, Copenhagen K, DK;

Attorneys:

Julie K. Staple

Dinsmore & Shohl LLP

Primary Examiner:

Jianfeng Song

Int. Cl.
CPC ...
A61K 9/24 (2006.01); A61K 31/506 (2006.01); A61K 9/20 (2006.01); A61K 31/198 (2006.01); A61K 31/165 (2006.01); A61K 9/00 (2006.01); A61K 31/422 (2006.01); A61K 9/48 (2006.01); A61K 45/06 (2006.01); A61K 31/216 (2006.01); A61K 31/454 (2006.01); A61K 9/28 (2006.01); A61K 9/50 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61K 31/4545 (2006.01);
U.S. Cl.
CPC ...
A61K 9/209 (2013.01); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/2009 (2013.01); A61K 9/2054 (2013.01); A61K 9/2866 (2013.01); A61K 9/485 (2013.01); A61K 9/4808 (2013.01); A61K 9/4866 (2013.01); A61K 9/5084 (2013.01); A61K 31/165 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/422 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.

Find Patent Forward Citations

Loading…